TD Cowen raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $35 from $30 and keeps a Buy rating on the shares. The firm updated its model following Q4 results and Management increased full-year 2026 guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $35 from $32 at Morgan Stanley
- Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
- Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
- Arcutis Biotherapeutics price target raised to $34 from $30 at H.C. Wainwright
- Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating